Miconazole is an imidazole derivative with a wide spectrum of activity against Gram-positive cocci and against most fungi and yeasts of medical interest (Hoeprich & Goldstein 1974 , Holt 1974 , Levine et al. 1975 , Negroni & Rodriguez 1973 , Sawyer et al. 1975a , Shadomy & Paxton 1975 , Stevens et al. 1976 , Sung & Grendahl 1977 , Van Cutsem & Theinpont 1972 . It was synthetized in this laboratory nine years ago (Fig 1) . The drug is being widely used for the topical treatment of fungal infections of the skin and nails and for the treatment of vaginal candidosis (Sawyer et al. 1975a, b (Clarysse 1975 , Sung & Grendahl 1977 where intravenous treatment alone had failed in some cases. Indeed, after intravenous treatment, miconazole concentrations in cerebrospinal fluid are less than one-tenth of plasma concentrations (Hoeprich & Goldstone 1974 , 1975 , Snoeckx et al. 1972 Table 2 ) and might be responsible for the treatment failures. In aspergilloma, miconazole did not remove the fungus ball. But severe symptoms due to active disease such as chronic coughing abundant expectoration, hamoptysis and febrile episodes were markedly reduced or disappeared. The number ofcolonies in the culture always decreased and the number of precipitin lines in the serum decreased in all cases except one. Unfortunately, most of these aspergilloma patients relapsed several months after the miconazole treatment.
Finally, some striking effects in patients with antibiotic-resistant fever of unknown origin should be mentioned. All were cancer patients without evidence of mycotic infection. In 5 of 7 cases, fever subsided within a few days of intravenous treatment. In at least one of these patients, miconazole was considered to be life saving.
Oral Administration
Oral miconazole was used mainly to reduce the intestinal yeast flora (Brugmans et al. 1972 , Svejgaard 1977 ; to prevent invasion from the digestive tract in debilitated patients (Michaux et al. 1977 , Ringoir & de Broe 1972 and to cure oral thrush in infants and adults. In all of these conditions, the drug was highly effective (Table 3) .
Oral miconazole also cured dermatophyte skin infections (though hair infections responded less well (Borelli & Marcano 1976 , Brugmans et al. 1972 ) and systemic mycoses caused by very sensitive organisms such as paracoccidioides, blastomyces and histoplasma (sensitivity class 1, Table 3 ). Some patients with systemic candidosis 10- 10.1 0.011 (Fransen & Van Kamp 1974 , Michaux et al. 1977 , aspergillosis (Lens 1973), coccidioidomycosis (Stevens et al. 1976) or with a phialophora infection failed to respond to oral miconazole but responded to intravenous treatment. These fungi belong to sensitivity class 2.
The apparently reduced response of certain class 2 fungi may be related to lower blood levels after oral treatment.
BloodLevels
Blood levels at the end of an intravenous infusion of a therapeutic dose of miconazole (Fig 2) are between 1 and 10 ,ug/ml in most patients (Boelaert et al. 1975 , Hoeprich & Huston 1974 , Hoeprich & Goldstein 1974 , Lewi et al. 1977 , Stevens et al. 1976 , Sung & Grendahl 1977 . Such a high level is not seen after oral administration of the same dose (Heykants et al. 1977) . Class 2 fungi (candida, cryptococcus, coccidioides) are inhibited by miconazole concentrations of 1 to 10 Kg/ml in vitro. If similar blood levels are needed for in vivo inhibition, systemic mycoses caused by class 2 fungi should preferentially be treated by intravenous miconazole. Class 1 fungi (dermatophytes, paracoccidioides, blastomyces and histoplasma) that are inhibited at concentrations of 0.1 ,ug/ml or less in vitro should be more responsive to oral miconazole.
The doses generally used for intravenous infusion varied from 600-1400 mg (max 3600 mg) daily, divided over one to three doses. In babies, an intravenous dose of 15 mg/kg twice daily was used uneventfully (Avognon 1973 , Berger 1974 . The usual oral dose in adults was 0.5-1.0 g three times daily. al. 1975 ), but none were seen when miconazole was given by slow intravenous infusion to patients.
Occasional side effects were chills, dizziness, itching, skin rash and diarrhoea. At high dose levels loss of appetite, nausea and vomiting were seen.
Intrathecal injections (Clarysse 1975 , Sung & Grendahl 1977 and direct instillations into the urinary tract (Daneels et al. 1974 , Fransen & Van Kamp 1974 , Michielsen 1974 , ,Roelandts et al. 1977 , Van Roost 1974 , the bronchi (Daneels et al. 1974 , Gailly 1974 , Jansen 1973 , Kipka 1974 , Renoirte 1974 , Van den Bergn 1974 , Veening 1974 , Weisburd 1976 or infected wounds (Ducheyne 1975 , Goenen 1977 , Mahieu 1974 caused no irritation and were well tolerated. Phlebitis has been reported with an early formulation.
Metabolism, excretion and plasma concentrations are not significantly influenced by renal insufficiency (Boelaert et al. 1975 , Lewi et al. 1977 nor by repeated administration (Brugmans 1972) .
Conclusion
It seems fair to conclude that miconazole is a major acquisition in antimycotic therapy. This drug can be given to seriously ill patients without danger. It causes little discomfort and is highly effective in a large number of mycotic infections. Drug induced resistance has not been reported.
Because of all these properties, miconazole is likely to become the drug of first choice in the treatment of many systemic mycoses.
Summary
Intravenous treatment with miconazole brought about the recovery of 90 % of patients with gastrointestinal or systemic candidosis. Miconazole given by the same route has also been found effective in the treatment of cryptococcosis, coccidioidomycosis, and paracoccidioidomycosis. Cryptococcal and coccidioidal meningitis have been cured by combined intravenous and intrathecal instillation, although treatment of aspergillosis has presented difficulty.
Oral treatment was effective in curing dermatophyte skin infections and systemic mycoses caused by sensitive organisms such as paracoccidioides, blastomyces and histoplasma.
The question of blood levels following oral and intravenous administration is discussed.
Side effects of the drug were few, and included chills, dizziness, skin rash, itching and diarrhcea. Thus miconazole can safely be given to seriously ill patients. Its behaviour in the body is not influenced by renal insufficiency and no drug induced resistance has been reported. (1976) 
